The company’s future financing is unclear and the investor calendar is empty. A good situation for current owners? Not a single negative-toned message has come out regarding Bex results or from any researcher regarding the science. Certainly, there are cautious and expectant comments, as Dr. Zeidan expressed in his first Faron webinar he participated in. I don’t remember what the topic was or if results have matured from it, I don’t know. Does anyone have memory/info on that?
The pipeline is progressing and news of the next financing must come to light soon. Faron is a phase 2 company and if that changes now, it’s a big game changer and at the same time, long-term plans have been redone. The Traumakine experience is there and the big money targets for the solid tumor side have been communicated. Hiring Bono, Ralph, and Jurriaan and paying the bank doesn’t look like a strategy change.
However, Money and those who have it talk and rule, no matter how much one is in the driver’s seat. It would be great to hear an interview with Juho to see if he still feels like he’s in the driver’s seat?
Bex is the Jalkanens’ life’s work from decades ago and they have surely timed the market entry for the best window, considering patents are expiring and no competitor is in sight. It’s also good to remember that hundreds of millions have flowed into the company to advance Bex from old and new parties. Nowadays, when information is more easily available about everything, I reckon that financiers get better data, and since money finds its way to money more and more often in today’s world, that’s likely the direction this is heading too.
Around Hikka’s anniversary, there could be positive news about blood cancers. Or could it be that the big picture strategy has been changed after all, so that e.g. the start of Phase 3 has been postponed and now they are first seeing what Finnprove, Bexar, Blaze, Matins -02 bring to the table. A good player and especially a businessman can change even a major strategy on the fly, for example, due to and above all as a result of partner discussions. Especially when we’re talking about hundreds of millions and even billions of euros, which were shown in those slides of Ralph’s former company.
Something big will likely happen before the Annual General Meeting at the end of March. Or otherwise, they might as well book the Gatorade [Center] for their meeting, when the “lottery folk” sign up for Turku on March 30, 2026.